Tyrosinase 酪氨酸酶（鼠單克隆抗體）

廣州健侖生物科技有限公司

酪氨酸酶(Tyrosinase)又名單酚單氧化酶，催化酚類化合物(如酪氨酸)的氧化，廣泛存在于動(dòng)植物中。Tyrosinase在黑色素及其他色素的生成過(guò)程中起催化作用，存在于黑色體中。其基因的突變會(huì)導(dǎo)致I型眼-皮膚白化?。òl(fā)病率1/17000）。該抗體特異性的表達(dá)于黑色素病變組織中，如惡性黑色素瘤、黑色素病變的神經(jīng)纖維瘤，上皮來(lái)源的癌*不表達(dá)該抗體。

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

Tyrosinase 酪氨酸酶（鼠單克隆抗體）

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞漿

克隆號(hào)：T311

同型：IgG

適用組織：石蠟/冰凍

陽(yáng)性對(duì)照：惡性黑色素瘤/皮膚色素痣

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時(shí)間：30-60min

Tyrosinase

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

艾布拉姆森癌癥中心研究人員諾埃爾·弗雷說(shuō)，“我們的試驗(yàn)結(jié)果說(shuō)明，CTL019療法可以對(duì)先前治療失敗的病人產(chǎn)生持久療效，同時(shí)不必使用其他補(bǔ)充療法”。這對(duì)于接受干細(xì)胞移植后癌癥復(fù)發(fā)或者沒(méi)有找到捐獻(xiàn)者的病人來(lái)說(shuō)是一個(gè)新的希望。
2014年7月美國(guó)食品和藥物管理局賦予CTL019療法“治療學(xué)發(fā)現(xiàn)”稱號(hào)，CTL019療法是*個(gè)性化細(xì)胞療法，在治療效果上顯示出重大優(yōu)勢(shì)，美國(guó)已在多家醫(yī)院開(kāi)始這種療法的測(cè)試。
據(jù)日本《朝日新聞》16日?qǐng)?bào)道，日本一化妝品公司宣布，成功使用iPS細(xì)胞(人工多能干細(xì)胞)實(shí)現(xiàn)了“返老還童”，將一位67歲日本男性的皮膚細(xì)胞恢復(fù)到和他本人36歲時(shí)的皮膚基本相同狀態(tài)。
據(jù)悉，該男性自1980年以來(lái)，一直定期提供36歲-67歲間五個(gè)不同年齡段的皮膚細(xì)胞，并由京都大學(xué)ips細(xì)胞研究所將其轉(zhuǎn)化為iPS細(xì)胞。
經(jīng)化妝品公司分析，作為老化指標(biāo)的染色體狀態(tài)在五個(gè)年齡段均有所恢復(fù)，連67歲時(shí)采集的皮膚細(xì)胞也恢復(fù)到了和36歲時(shí)大致相同的狀態(tài)。
該公司稱，將使用此研究結(jié)果闡明皮膚老化機(jī)制。目前雖尚處于基礎(chǔ)研究階段，但從長(zhǎng)遠(yuǎn)來(lái)看，這將會(huì)推動(dòng)針對(duì)個(gè)人、不同敏感源的定制化妝品開(kāi)發(fā)

Noel Frey, a researcher at the Abramson Cancer Center, said, "Our results demonstrate that CTL019 can produce long-lasting effects in previously unsuccessful patients without the need for other complementary therapies." This is a new hope for patients who have relapsed after stem cell transplantation or have not found a donor.
In July 2014, the US Food and Drug Administration awarded the title of "Therapeutics Discovery" to CTL019 Therapy. CTL019 Therapy is the first personalized cell therapy that shows major advantages in treatment effectiveness. The United States has started this therapy in several hospitals test.
According to Japan's "Asahi Shimbun" reported on the 16th, a cosmetics company in Japan announced the successful use of iPS cells (artificial pluripotent stem cells) to achieve "rejuvenation" will be a 67-year-old Japanese male skin cells and his return to 36 years old The skin is basically the same state.
It is reported that since 1980, the man has regularly provided skin cells of five different ages ranging from 36 to 67 years old and has been transformed into iPS cells by the ips cell research institute of Kyoto University.
Analyzed by the Cosmetics Company, the status of chromosomes as an indicator of aging recovered in all five age groups, and the skin cells collected at 67 were also restored to the same state as those at 36 years of age.
The company said it will use the results of this study to elucidate the mechanism of skin aging. Although it is still in the basic research phase, it will promote the development of customized cosmetics targeting individuals and sensitive sources in the long run